BioMarin Pharmaceutical Inc. (BIT:1BMRN)
Italy · Delayed Price · Currency is EUR 44.72
-1.93 (-4.14%)
At close: Oct 10, 2025
BioMarin Pharmaceutical Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2005 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2005 - 2019 |
Net Income | 657.24 | 426.86 | 167.65 | 141.56 | -64.08 | 854.03 | Upgrade |
Depreciation & Amortization | 83.25 | 96.43 | 104.39 | 101.97 | 108.04 | 105.17 | Upgrade |
Stock-Based Compensation | 180.64 | 201.57 | 207.1 | 196.31 | 197.26 | 189.71 | Upgrade |
Other Adjustments | 131.72 | 64.38 | 16.67 | -167.55 | -2.72 | -838.61 | Upgrade |
Change in Receivables | -157.95 | -57.91 | -190.44 | -82.03 | 65.57 | -59.04 | Upgrade |
Changes in Inventories | -88.58 | -63.53 | -157.06 | -68.26 | -35.06 | -61.15 | Upgrade |
Changes in Accounts Payable | 25.13 | -32.24 | 68.85 | 59.02 | 15.69 | -87.03 | Upgrade |
Changes in Other Operating Activities | -71.22 | -62.72 | -57.9 | -5.1 | 19.83 | -17.72 | Upgrade |
Operating Cash Flow | 766.77 | 572.84 | 159.26 | 175.9 | 304.54 | 85.37 | Upgrade |
Operating Cash Flow Growth | 133.16% | 259.69% | -9.46% | -42.24% | 256.75% | 76.88% | Upgrade |
Capital Expenditures | -71.86 | -85.42 | -96.69 | -120.96 | -95.58 | -114.31 | Upgrade |
Sale of Property, Plant & Equipment | - | 10 | - | 103.33 | - | 67.16 | Upgrade |
Purchases of Intangible Assets | -3.75 | -11.99 | -10.92 | -10.58 | -23.65 | -23.21 | Upgrade |
Purchases of Investments | -417.22 | -410.25 | -868.5 | -611.81 | -937.14 | -538.37 | Upgrade |
Proceeds from Sale of Investments | 511.11 | 633.02 | 864.86 | 620 | 691.05 | 555.83 | Upgrade |
Other Investing Activities | - | 1.14 | - | - | -0.99 | -0.72 | Upgrade |
Investing Cash Flow | 19.42 | 136.49 | -111.24 | -20.03 | -366.31 | -53.62 | Upgrade |
Long-Term Debt Issued | - | - | - | - | - | 585.75 | Upgrade |
Long-Term Debt Repaid | - | -494.99 | - | - | -3.04 | -381.91 | Upgrade |
Net Long-Term Debt Issued (Repaid) | - | -494.99 | - | - | -3.04 | 203.84 | Upgrade |
Issuance of Common Stock | 20.37 | 49.28 | 69.35 | 69.33 | 49.19 | 71.91 | Upgrade |
Repurchase of Common Stock | -61.91 | -77.56 | -76.32 | -54.28 | -45.81 | -94.64 | Upgrade |
Net Common Stock Issued (Repurchased) | -41.54 | -28.28 | -6.97 | 15.05 | 3.39 | -22.73 | Upgrade |
Other Financing Activities | - | -3.18 | -11.76 | -33.7 | -0.4 | - | Upgrade |
Financing Cash Flow | -539.65 | -526.45 | -18.73 | -18.65 | -0.05 | 181.12 | Upgrade |
Effect of Exchange Rate Changes on Cash and Cash Equivalents | -4.88 | 4.83 | 1.31 | 0.03 | -0.06 | -1.15 | Upgrade |
Net Cash Flow | 241.67 | 187.72 | 30.6 | 137.26 | -61.88 | 211.71 | Upgrade |
Beginning Cash & Cash Equivalents | 972.15 | 755.13 | 724.53 | 587.28 | 649.16 | 437.45 | Upgrade |
Ending Cash & Cash Equivalents | 1,214 | 942.84 | 755.13 | 724.53 | 587.28 | 649.16 | Upgrade |
Free Cash Flow | 694.91 | 487.42 | 62.57 | 54.94 | 208.96 | -28.95 | Upgrade |
Free Cash Flow Growth | 42.57% | 679.02% | 13.88% | -73.71% | - | - | Upgrade |
FCF Margin | 22.68% | 17.08% | 2.59% | 2.62% | 11.32% | -1.56% | Upgrade |
Free Cash Flow Per Share | 3.53 | 2.48 | 0.33 | 0.29 | 1.14 | -0.15 | Upgrade |
Levered Free Cash Flow | 533.95 | -215.61 | 29.24 | 108.22 | -54.2 | 882.83 | Upgrade |
Unlevered Free Cash Flow | 483.91 | 214.5 | 26.76 | -95.01 | -57.1 | 546.46 | Upgrade |
Updated Jun 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.